expression were significantly correlated with a reduction in the overall survival times in all patients harboring gliomas.
The gene encoding for survivin has been located on chromosome 17q25. In addition, two novel splice variants of survivin oriented at the same locus were recently described: survivin-2B and survivin-⌬Ex3. 21 Survivin-2B retains 69 bp of intron 2 as a novel exon (exon 2B) between exon 2 and exon 3. Survivin-⌬Ex3 is missing 118 bp of exon 3. Both sequence alterations cause changes in the structure of the corresponding proteins, including changes in the BIR domain. Based on their transfection experiments, Mahotka, et al., 21 reported that the role of survivin-⌬Ex3 might be the conservation of antiapoptotic properties, whereas the role of survivin-2B might be the reduction of the antiapoptotic potential compared with that in survivin. Moreover, in a subsequent study, Mahotka, et al., 20 succeeded in quantifying the mRNA expression of survivin splice variants and analyzed the expression pattern of these variants in renal cell carcinoma specimens. They observed a significant decrease in the mRNA ratio between survivin-2B and survivin in the late tumor stages; however, the relationship between survivin-⌬Ex3 mRNA expression and renal cell carcinoma development was not clearly identified.
In this study, we measured the expression level of survivin and its splice variants in tumor cell lines, including glioblastoma cell lines, brain tumor samples, and normal templates, by using quantitative RT-PCR. This is the first report in which the expression of survivin splice variants in gliomas and normal templates has been quantitatively analyzed. We also investigated the relationship between survivin mRNA and survivin splice variants mRNA as well as the expression and histological malignancy of the corresponding brain tumors in humans.
Materials and Methods

Tumor Cell Lines and Cell Cultures
The tumor cell lines used in this study were as follows: glioblastoma cell lines (U251MG, U87MG, and U118MG), neuroblastoma cell lines (SK-N-AS and SH-SY5Y), colorectal carcinoma cell lines (HT29, LOVO, and CACo2), and a lung cancer cell line (A549). All of the glioblastoma cell lines and two of the colorectal carcinoma cell lines (HT29 and LOVO) were purchased from American Type Culture Collection (Manassas, VA). The SK-N-AS, SH-SY5Y, CACo2, and A549 were kindly provided by A. Nakagawara (Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba, Japan). The U251MG, U87MG, and U118MG were cultured in DMEM (Gibco-BRL, Tokyo, Japan). The SK-N-AS, SH-SY5Y, CACo2, and A549 were cultured in RPMI-1640 (Nissui, Tokyo, Japan), HT29 in McCoy 5A medium (Gibco-BRL, Grand Island, NY), and LOVO in F12 medium (Gibco-BRL). All media were supplemented with 10% heat-inactivated FBS (Gibco-BRL), except in the serum reduction experiments. In some experiments in which U87MG cells were used, survivin expression was analyzed with special reference to the serum reduction. For these experiments, cells were detached with trypsin-ethylenediaminetetraacetic acid (Gibco-BRL), washed three times with serum-free DMEM, and cultured in DMEM supplemented with 10% or 1% FBS or serum-free DMEM. After 48 hours in culture, cells were processed for the analysis of mRNA expression, as described later. All cells were cultured at 37C in an atmosphere with 5% CO 2 . A set of cDNA from normal fetal tissues was purchased from Clontech (human fetal MTC panel, K1425-1; Tokyo, Japan) and included cDNA from brain, lung, liver, heart, kidney, skeletal muscle, spleen, and thymus. The template of a normal adult brain was purchased from OriGene Technologies, Inc. (human first-strand cDNA, human brain, CH-1001; Rockville, MD). These fetal and adult brain templates were a mixture of glia, neurons, and vascular cells.
Brain Tumor Samples
Twenty-four brain tumor specimens and one normal brain sample from an adult were obtained from 24 consecutive patients with brain tumors. The patients underwent operation at the Department of Neurosurgery, Osaka Medical College, Japan, between April 2001 and August 2002. All patients provided their informed consent to participate in these experiments after reviewing an explanatory booklet approved by the Osaka Medical College Ethics Committee. Pathologists at the Osaka Medical College Hospital provided histopathological diagnoses and calculated the MIB-1 index. Tissue sections were immunohistochemically stained with the mouse monoclonal antibody MIB-1 (Dako Cytomation, Kyoto, Japan) to detect the human antigen Ki-67, and the MIB-1 index was counted as a percentage of nuclear staining to the total number of cells counted. At least 10 high-power fields were chosen randomly, and 1000 cells were counted for each case.
Total RNA Isolation
Total RNA was isolated both from cells cultured to 80% confluence and from frozen brain tumor samples by using the acid guanidinium-phenol-chloroform method with the aid of Isogen (Nippon Gene, Toyama, Japan), according to the manufacturer' s instructions. Contaminating chromosomal DNA was digested with DNAse 1 (Gibco-BRL Life Technologies, Inc., Gaithersburg, MD) according to the manufacturer' s instructions. Isolated total RNA pellets were dissolved in RNase-free, diethylpyrocarbonate-treated water.
First-Strand cDNA Synthesis
For first-strand cDNA synthesis, 5 g total RNA, 5 l bulk firststrand cDNA reaction mixes (Amersham Pharmacia Biotech, Piscataway, NJ), 1 l dithiothreitol solution, 1 l pd(N) 6 primer, and diethylpyrocarbonate-treated water were mixed to make a total volume of 15 l. The RT reactions were incubated at 37C for 60 minutes. Finally, cDNA solution was diluted to a total volume of 300 l.
Quantitative RT-PCR
Quantitative PCR amplifications were performed with a LightCycler (Roche Diagnostics, Tokyo, Japan). As an internal control, the expression of G6PDH mRNA was measured. Reverse transcription-PCR analysis was performed in a blinded manner, that is, without prior knowledge of the histopathological diagnosis. Two microliters cDNA mixture was subjected to amplification in a 20-l reaction mixture containing 2 l LightCycler-FastStart Mix (Taq DNA polymerase, reaction buffer, and deoxynucleoside triphosphate mix; Roche Molecular Biochemicals, Mannheim, Germany), 1 l sense primer (10 pM), 1 l antisense primer (10 pM), 1 l hybridization probe R (8 pM), 1 l hybridization probe F (4 pM), 3 mM MgCl 2 , and sterile distilled water. The PCR conditions were as follows: initial denaturation at 95C for 15 minutes followed by 40 cycles of denaturation at 95C for 10 seconds, annealing at 62C for survivin, survivin-2B, and survivin-⌬Ex3 or at 63C for G6PDH for 10 seconds, and extension at 72C for 10 seconds. A standard curve was generated using fluorescent data from the serial dilutions of the plasmid including a single PCR product.
The primer pairs and hybridization probes for survivin, survivin-2B, survivin-⌬Ex3, and G6PDH mRNA were as follows (Fig. 1) . The sequence of the common forward primer for survivin, survivin-2B, and survivin-⌬Ex3 was 5Ј-CCACCGCATCTCTACATTCA-3Ј (NCBI BC008718 90-109, NCBI AB028869 74-93, and NCBI BC000784 102-121). To distinguish between survivin and either of its splice variants, the sequences of reverse primers were designed to correspond to exon/exon borders of the complementary strand. The sequence of the reverse primer for survivin mRNA was 5Ј-TAT-GTTCCTCTATGGGGTCG-3Ј (NCBI BC008718 255-274), for survivin-2B mRNA 5Ј-AGTGCTGGTATTACAGGCGT-3Ј (NCBI AB028869 268-287), and for survivin-⌬Ex3 mRNA was 5Ј-TTT-CCTTTGCATGGGGTC-3Ј (NCBI BC000784 268-285). The sequence of the common hybridization probe F for survivin, survivin-2B, and survivin-⌬Ex3 was 5Ј-CAAGTCTGGCTCGTTCTCAGT-GGG-3Ј-FITC (NCBI BC008718 159-179, NCBI AB028869 143-163, and NCBI BC000784 171-191, respectively). The sequence of the common hybridization probe R for survivin, survivin-2B, and survivin-⌬Ex3 was LC-5Ј-CAGTGGATGAAGCCAGCCTCG-3Ј-P (NCBI BC008718 181-204, NCBI AB028869 165-188, and NCBI BC000784 193-216, respectively). The sequence of the forward primer for G6PDH mRNA was 5Ј-TGGACCTGACCTACGGCA-ACAGATA-3Ј (NCBI BC000337 1321-1345). The sequence of the reverse primer for G6PDH mRNA was 5Ј-GCCCTCATACTG-GAAACCC-3Ј (NCBI BC000337 1559-1577). The sequence of the hybridization probe F for G6PDH mRNA was 5Ј-TTTTCACCC-CACTGCTGCACC-3Ј-FITC (NCBI BC000337 1453-1473). The sequence of the hybridization probe R for G6PDH mRNA was LC-5Ј-GATTGAGCTGGAGAAGCCCAAGC-3Ј (NCBI BC000337 1475-1497). Data for survivin, survivin-2B, and survivin-⌬Ex3 were normalized with the data for G6PDH. The expression levels for survivin and its splice variants were expressed as 1000 ϫ survivin/ G6PDH or 1000 ϫ survivin splice variants/G6PDH, respectively.
Sequence Analysis
To confirm the identity of the PCR products, bands of the products were eluted from agarose gels by using a gel extraction kit (QIAquick; Qiagen, Tokyo, Japan), ligated into the pGEM-T cloning vector (Promega, Madison, WI), and cloned according to standard protocols. Plasmid DNA was recovered using a Plasmid Mini kit (Qiagen), cycle sequenced, and analyzed in an ABI PRISM 310 (Applied Biosystems, Osaka, Japan) by using T7 or SP6 site-specific primers. The sequences of the PCR products were compared with those in GenBank and were found to be identical (data not shown).
Statistical Analysis
A Mann-Whitney U-test and Fisher protected least-significant difference test were used to determine the association between survivin mRNA expression and the individual tumor cell lines and brain tumor samples. A Pearson correlation coefficient and a simple regression plot were used to determine the correlation between survivin mRNA expression and the MIB-1 index. Probability values less than 0.05 were considered to indicate statistical significance.
Results
Expression of mRNA of Survivin and its Splice Variants in Cell Lines
Quantitative RT-PCR was performed to determine the expression levels of mRNA of survivin and its splice vari- * Data for survivin, survivin-2B, and survivin-⌬Ex3 were normalized with the data for G6PDH. Values are expressed as the means Ϯ SE. † Survivin mRNA expression in U251MG and U87MG was significantly higher than that in the adult brain template (p Ͻ 0.0001 and p Ͻ 0.05, respectively) and significantly higher than that in all of the other cell lines tested (p Ͻ 0.05).
‡ Survivin-2B mRNA expression in U251MG and U87MG was significantly higher than that in the other cell lines and normal fetal panels, with the exception of HT29 and the normal adult brain template (p Ͻ 0.05).
§ Survivin-⌬Ex3 mRNA expression in U251MG and U87MG was higher than that in the other cell lines and normal fetal panels, with the exception of U118MG and the normal adult brain template (p Ͻ 0.05). Arrows indicate the position of the RT-PCR primer pairs. The forward primer was common to survivin, survivin-2B, and survivin⌬Ex3. The three reverse primers were specific for survivin, survivin-2B, and survivin-⌬Ex3, respectively. White circle next to black circle indicates the position of the hybridization probes. This hybridization probe pair was common to survivin, survivin-2B, and survivin-⌬Ex3.
ants in the nine tumor cell lines (including three glioblastoma cell lines), the normal adult brain template, and normal fetal tissue panels (brain, lung, liver, kidney, heart, skeletal muscle, spleen, and thymus tissue; Table 1 ). Data for survivin, survivin-2B, and survivin-⌬Ex3 were normalized with the data for G6PDH. Values for the expression of survivin splice variants were expressed as 1000 ϫ survivin splice variants/G6PDH. The values in cell lines were expressed as the means Ϯ SE of five independent assays. Survivin mRNA expression was detected in all tumor cell lines and normal templates. In the normal fetal tissues in this study, all of which have been previously reported to express survivin mRNA, 1-3 the mean level of survivin mRNA expression was 217.36 Ϯ 78.23. A particularly high expression level of survivin was demonstrated in the fetal liver. The survivin expression level was 112 in the fetal brain. Survivin-2B and survivin-⌬Ex3 expressions were undetectable in the fetal brain and heart cDNA templates. In the normal adult brain template, the expression of survivin mRNA was lower than that in the normal fetal templates. Furthermore, survivin-2B and survivin-⌬Ex3 were undetectable in the normal adult brain cDNA template. Among the cell lines tested, high expression levels of survivin mRNA were detected in the glioblastoma cell lines U251MG and U87MG. On the other hand, the level of survivin mRNA in the lung cancer cell line A549 was lower than that in the normal fetal tissue panels and almost equal to that in the normal adult brain template. In U118MG and HT29, survivin mRNA expression was almost equal to the mean level in normal fetal tissue panels. In LOVO, CACo2, SK-N-AS, and SH-SY5Y, the survivin mRNA expression level was slightly less than the mean level in normal fetal tissue panels. The Fisher protected least-significant difference analysis revealed that survivin mRNA expression in U251MG and U87MG was significantly higher than that in the adult brain template (p Ͻ 0.0001 and p Ͻ 0.05, respectively). In addition, survivin mRNA expression in both of these glioblastoma cell lines was significantly higher than that in any of the other tumor cell lines (p Ͻ 0.05). Survivin-2B mRNA expression levels in U251MG and U87MG were significantly higher than those in other cell lines and normal fetal panels, with the exception of HT29 and the normal adult template (p Ͻ 0.05). Survivin-⌬Ex3 mRNA expression levels in U251MG and U87MG were higher than those in other cell lines and normal fetal panels, with the exception of U118MG and the normal adult template (p Ͻ 0.05).
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Quantitative 
Effect of Serum Reduction for Survivin mRNA Expression
To determine the effects of the cell proliferation state on the expression of survivin mRNA, we performed serum reduction in culture medium by using U87MG glioblastoma cells. Reduction of FBS in culture medium apparently affected cell proliferation (data not shown). The more serum added in culture, the higher the expression level of survivin mRNA (Fig. 2) . These survivin mRNA expression data were already normalized by the housekeeping gene G6PDH mRNA, and therefore the increase in survivin mRNA seems mainly an effect on the proliferative state of individual cells.
Expression of Survivin mRNA in Brain Tumor Samples
To determine the expression level of survivin mRNA in brain tumor samples, we examined 25 brain tumor samples by using quantitative RT-PCR (Table 2) . For the following analysis, we classified the tumor samples as malignant or benign and as gliomas or nongliomas. The brain tumor samples included nine gliomas, 15 nongliomas, and one normal brain from an adult. Among the nine gliomas, there were eight malignant gliomas (glioblastoma, anaplastic astrocytoma, and medulloblastoma) and one benign glioma (pilocytic astrocytoma). The 15 nongliomas consisted of four malignant (metastatic brain tumor and atypical meningioma) and 11 benign brain tumors (meningioma, schwannoma, and pituitary adenoma). Survivin mRNA expression was detectable in all samples except for the pilocytic astrocytoma, which is well known to have an extremely benign prognosis. 6 In the normal brain sample from an adult, a negligible amount of survivin mRNA was detected, and survivin-2B and survivin-⌬Ex3 mRNA were not detectable at all. The expression pattern in the normal brain sample was similar to that in the normal adult brain template.
The association between survivin mRNA expression and histopathological malignancy is shown in Fig. 3A . Malignant brain tumors consisted of 12 cases including four glioblastomas, three anaplastic astrocytomas, one medulloblastoma, one metastatic brain tumor, and three atypical meningiomas. There were 12 cases of benign brain tumors including one pilocytic astrocytoma, six meningiomas, two schwannomas, and three pituitary adenomas. The expression of survivin mRNA was significantly greater in malignant brain tumors than in benign brain tumors (p Ͻ 0.0005). We found that expression of survivin mRNA was significantly correlated with histopathological malignancy. Figure  3B shows the survivin mRNA expression for gliomas and nongliomas. The nine cases of glioma included four glioblastomas, three anaplastic astrocytomas, one pilocytic astrocytoma, and one medulloblastoma. The 15 cases of nonglioma included one metastatic brain tumor, three atypical meningiomas, six meningiomas, two schwannomas, and three pituitary adenomas. Survivin mRNA expression was significantly higher in the gliomas (p Ͻ 0.05). Among the astrocytic tumors, survivin mRNA expression was significantly higher in glioblastoma than in anaplastic astrocytoma or pilocytic astrocytoma (p Ͻ 0.0001 and p = 0.002, respectively). No statistical difference in survivin mRNA expression was observed between anaplastic astrocytoma and pilocytic astrocytoma.
Expression Patterns of Survivin Splice Variants in Brain Tumor Samples
To speculate on the functional role of the survivin splice variants in the brain tumor samples, we compared the ratio of survivin splice variants/survivin among brain tumor samples. The ratio of survivin-⌬Ex3/survivin was significantly increased in malignant brain tumors (p Ͻ 0.05; Fig. 4A ) and gliomas (p Ͻ 0.05; Fig. 4B ). As for survivin-2B, there was no statistical difference in the ratio of survivin-2B/survivin between benign and malignant brain tumors (Fig. 5A) or between gliomas and nongliomas (Fig. 5B) . Nevertheless, it was apparent that the ratio of survivin-2B/survivin was relatively high in both benign brain tumors and nongliomas. The expression pattern of splice variants was dominant for survivin-⌬Ex3 in malignant brain tumors and gliomas, and dominant for survivin-2B in benign brain tumors and nongliomas. In our limited series of astrocytic tumors, there was no statistical difference in the ratios of survivin-2B/survivin or survivin-⌬Ex3/survivin.
Correlation Between Survivin mRNA Expression and MIB-1 Index in Brain Tumor Samples
Finally, we analyzed the correlation between survivin mRNA expression and the MIB-1 index in brain tumor samples (Fig. 6) . A significant correlation between survivin and the MIB-1 index was demonstrated (p Ͻ 0.001); the simple regression line was MIB-1 index = 0.011 ϫ survivin (R 2 = 0.871). Only in gliomas was a more significant correlation recognized between survivin mRNA expression and the MIB-1 index (p Ͻ 0.001); the simple regression line was MIB-1 index = 0.011 ϫ survivin (R 2 = 0.898).
Discussion
In the present study, we analyzed the expression of survivin and its splice variants in cell lines, brain tumor samples, and normal templates by using quantitative RT-PCR. In previous reports on the expression of the mRNA of survivin and its splice variants, researchers have performed mainly qualitative RT-PCR analysis or Northern blot analysis. 12, 22, 26, 27 Even those studies in which TaqMan RT-PCR has been used, investigators have measured only survivin mRNA, not the mRNA of survivin splice variants. 4, 14, 23 The first successful quantitative analysis of survivin splice variants was performed only recently by Mahotka, et al., 20 who studied renal cell carcinoma specimens.
There has been only one report of survivin expression in gliomas, which was published by Chakravarti, et al. 7 In this report, survivin protein expression in patients with glioma was analyzed with the aid of semiquantitative Western blot analysis and densitometry. These authors did not measure the expression of survivin splice variants. In the present study, we performed the first quantitative measurement of survivin and its splice variants in brain tumors and normal templates by using primer pairs specific for each of the two splice variants. Previous study data have indicated that survivin is expressed during fetal development, but not in most normal tissues in adults. [1] [2] [3] In contrast, recent study data have demonstrated survivin expression in normal tissues in adults, such as those of the skin, endometrium, endothelial cells, normal blood lymphocytes, pancreas, spleen, and colon. 5, 8, 10, 16, 24, 27 In their RT-PCR analysis, Hirohashi, et al., 10 reported low levels of survivin expression in all normal tissues tested in adults (stomach, small intestine, large intestine, spleen, lung, kidney, prostate, pancreas, heart, and thymus). Survivin-2B and survivin-⌬Ex3 were detectable only in the thymus, however. In our study, results of sensitive quantitative RT-PCR revealed that survivin mRNA was expressed in all normal fetal tissue panels and at a very low level in the normal adult brain template. Survivin-2B and survivin⌬Ex3 mRNA were undetectable in the fetal brain and heart and the adult brain template. Compared with the survivin mRNA expression in normal fetal brain templates, a very low level of survivin mRNA was expressed in the normal adult brain template, results consistent with our data for specimens of normal brain tissue as well as with the findings from a previous report. 5 Survivin mRNA was more highly expressed in the tumor cell lines than in the normal adult brain template; the single exception to this trend was in the cell line A549. Each of the cell lines LOVO, CACo2, SK-N-AS, and SH-SY5Y expressed less survivin mRNA than the mean level in the normal fetal panels. Both U251MG and U87MG expressed survivin mRNA more abundantly than any of the other tumor cell lines and the normal adult brain template. In addition, HT29 and U118MG expressed survivin mRNA at a level almost equal to that in the normal fetal templates. Our results indicate that in glioblastoma cell lines, especially U251MG and U87MG, abundant expression of survivin mRNA confers significant advantages for the growth of tumor cells.
We classified our brain tumor specimens into two different categories, that is, as pathologically malignant or benign and as gliomas or nongliomas. We then compared expression levels of survivin mRNA according to these classifications. The malignant brain tumors expressed survivin mRNA more abundantly than the benign brain tumors (p Ͻ 0.0005). In addition, gliomas expressed survivin mRNA more abundantly than nongliomas (p Ͻ 0.05). Chakravarti, et al., 7 reported in their study that increasing levels of survivin expression were significantly correlated with reduced overall survival times in all patients with gliomas. No clear correlation between survivin expression and histological malignancy was identified, however. In the present study, survivin mRNA was abundantly expressed, especially in glioblastoma samples. Unfortunately, we were unable to analyze the relationship between survivin mRNA expression and prognosis and World Health Organization classification, because the research period was so short and the number of cases so limited. Another larger study must be undertaken to determine these relationships.
We performed two different analyses to determine the relationship between survivin expression and cell proliferation. One analysis involved serum reduction in culture medium by using the U87MG glioma cells. The other analysis was applied to brain tumor samples to disclose the relationship between MIB-1 index and survivin mRNA expression. As stated earlier, the more serum added in culture medium, the greater the proliferation of cultured cells and the more survivin expression observed. The increase of survivin mRNA in cultured cells seemed to be dependent on the proliferative state of the cells. Survivin is thought to be expressed in the G2/M phase of the cell cycle, to deregulate apoptosis, and to promote abnormal cell survival, thereby conferring a significant growth advantage to tumor cells. 18 Furthermore, survivin is thought to be expressed in the G1 phase of the cell cycle and to promote cell cycle changes from the G1 to the S phase by activating cyclin-dependent kinase 4.
13 Note that MIB-1, a marker of cellular proliferation, is the monoclonal antibody developed against the Ki-67 antigen, which is present in G1, S, G2, and M phases of the cell cycle. In this study, we investigated the relationship between survivin mRNA expression and the MIB-1 index and found a significant positive correlation between these biological parameters (p Ͻ 0.001). The simple regression line was MIB-1 index = 0.011 ϫ survivin (R 2 = 0.871). This close correlation between survivin expression and MIB-1 index reveals the possibility that survivin may promote cell proliferation. Given the results of these two analyses, we speculate that survivin expression and cell proliferation are tightly linked. These results are consistent with data from a study in which hepatocellular carcinoma was investigated using proliferating cell nuclear antigen as a proliferation marker. 13 As stated in Results, relative survivin-⌬Ex3 mRNA expression was significantly increased in malignant brain tumors and gliomas, whereas there was no statistically significant difference in the relative survivin-2B mRNA expression comparing benign and malignant brain tumors, and gliomas and nongliomas. Mahotka, et al., 20 reported that the ratio between survivin-2B and survivin was significantly decreased in the late tumor stages of renal cell carcinoma. With respect to the ratio between survivin-⌬Ex3 and survivin, however, these authors recognized no significant difference in any of the tumor stages. Although our results differed from those of Mahotka, et al., both groups of researchers found that the expression patterns of splice variants were dominant for survivin-⌬Ex3 in malignant tumors and dominant for survivin-2B in benign tumors. Note that our results for gliomas and nongliomas may have been heavily influenced by the disproportion of the histopathological types represented, because our gliomas consisted of eight malignant tumors and one benign tumor and our nonglioma included four malignant and 11 benign tumors. As mentioned earlier, the transfection experiment data of Mahotka, et al., 21 indicated that the role of survivin-⌬Ex3 is preservation and the role of survivin-2B is the reduction of the antiapoptotic property compared with that of survivin. Both survivin-⌬Ex3 and survivin-2B contain modifications of the BIR domain. Nevertheless, these molecules still retain the ability to regulate their antiapoptotic property, although the mechanism of this regulation remains unclear. To determine the role of the survivin splice variants, further examinations are required.
Conclusions
Survivin mRNA was preferentially expressed in malig-nant brain tumor, particularly in glioblastoma. The expression patterns of the survivin splice variants were dominant for survivin-⌬Ex3 in malignant brain tumors and dominant for survivin-2B in benign brain tumors. Additionally, the expression level of survivin mRNA closely correlated with the MIB-1 index, a proliferation marker. Our results indicate that quantification of the transcript levels of survivin and its splice variants is useful in predicting the cell biological malignancy of brain tumors, independently of pathophysiological features. Furthermore, the relative quickness of quantitative RT-PCR analysis might render it useful as a supplementary diagnostic tool in making decisions regarding adjuvant therapy.
